Kura Oncology price target lowered to $37 from $40 at Wedbush

Wedbush analyst Robert Driscoll lowered the firm’s price target on Kura Oncology to $37 from $40 and keeps an Outperform rating on the shares following the Q2 results and clinical pipeline update. Enrollment of roughly 85 patients in the Phase 2 KOMET-001 registration-directed study of menin inhibitor ziftomenib has proceeded rapidly, and remains on track to finish by mid-2024, the analyst tells investors in a research note.